|
FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG
HeartCheck™ PEN to be marketed directly to over 500 Independent Retail Pharmacies in Ontario
TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) (“CardioComm Solutions” or the “Company”), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, announces they have entered into an agreement with a direct-to-pharmacy sales force for the introduction of the HeartCheck™ ECG PEN for sale into 517 independent retail pharmacies in Ontario. The Company confirms the HeartCheck™ ECG PEN will start to be available on the shelves of Ontario based independent retail pharmacies starting March 2015.
The start of pharmacy based sales was announced February 16th, 2015, when the Company confirmed the HeartCheck™ ECG PEN was available through participating stores of Canada's largest pharmacy chain. Of these, 300 locations are within the province of Ontario, the province that by far holds the greatest number of the pharmacies in Canada*. With the addition of as many as 517 independently owned Ontario pharmacies over the coming months, CardioComm Solutions will be implementing various media strategies to increased consumer awareness on the availability of the HeartCheck™ ECG PEN across Canada with a focus on sales in Ontario. CardioComm Solutions will be adding new participating pharmacy locations and will provide further updates on availability of the HeartCheck™ ECG PEN at www.theheartcheck.com.
The consumer and pharmacy markets are already familiar with measuring blood pressure and sugar levels but what about measuring how well a person's heart is beating? Is it irregular, fast, too slow, is it normal or not? Previously, figuring this out has meant a trip to the doctor or emergency room to get hooked up to an EKG machine but now anyone may test themselves by using the HeartCheck™ ECG PEN handheld device. Without the need for a physician prescription, this consumer product will open opportunities for better heart health monitoring. There is also an option for getting an ECG reviewed by the Company's SMART Monitoring ECG service with results provided back to the consumer within an hour. The Company has previously announced the use of its HeartCheck™ products and services in atrial fibrillation (AF) screening programs with the Heart and Stroke and academic university-based physicians and the on-line sales of the HeartCheck™ ECG PEN through cardiac arrhythmia advocacy groups as well as the Canadian Pharmacy.ca.
The HeartCheck™ ECG PEN lets you self-monitor your heart health whether it's to ensure continued good health or for use at the time symptoms such as a racing heart rate, palpitations, dizziness or irregular heartbeats are experienced. This Canadian innovation is the only device of its kind approved by Health Canada and cleared by the FDA for over-the-counter sales and its introduction represents the newest Class II medical device technology cleared for home-use in the past 40 years.
Intended not only for those actively interested in taking control of maintaining their heart health, the HeartCheck™ PEN is also for those living with chronic conditions such as hypertension, diabetes and congestive heart disease. Its use may help to identify the presence of AF and track signs for risk of sudden cardiac death such as prolonged QRS duration and QT intervals. AF is the most common arrhythmia in developed countries and is associated with a doubling of risk for dementia, a tripling of risk for heart failure, and a 40% to 90% increased risk for overall mortality, according to the Framingham Heart Study. Individuals with atrial fibrillation also have a very high risk of stroke that is three (3) to five (5) times greater than those without AF, according to the Canadian Heart and Stroke Foundation.
As a special bonus, CardioComm Solutions is offering ten (10) free ECG readings to those who purchase the HeartCheck™ ECG PEN through pharmacies during February, March and April 2015.
*January 1, 2015, statistics from the National Association of Pharmacy Regulatory Authorities
download pdf 
CardioComm Solutions' patented and proprietary
technology is used in products for recording,
viewing, analyzing and storing
electrocardiograms (ECGs) for diagnosis and
management of cardiac patients. Products
are sold worldwide through a combination of an
external distribution network and a North
American-based sales team. The Company has
earned the ISO 13485 certification, is HPB
approved, HIPAA compliant, and has received FDA
market clearance for its software devices.
CardioComm Solutions is headquartered in
Toronto, Canada, with offices in Victoria,
B.C.
FOR FURTHER
INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
Forward-looking
statements
This release may contain certain forward-looking
statements and forward looking information with
respect to the financial condition, results of
operations and business of CardioComm Solutions
and certain of the plans and objectives of
CardioComm Solutions with respect to these
items. Such statements and information reflect
management's current beliefs and are based on
information currently available to management.
By their nature, forward-looking statements and
forward-looking information involve risk and
uncertainty because they relate to events and
depend on circumstances that will occur in the
future and there are many factors that could
cause actual results and developments to differ
materially from those expressed or implied by
these forward-looking statements and
forward-looking information.
In evaluating these statements, readers should:
specifically consider risks discussed under the
heading "Risk Factors" in the Company's Annual
Information Form, available at www.sedar.com;
not to place undue reliance on forward-looking
statements and forward-looking information; be
aware. the Company does not assume any
obligation to update the forward-looking
statements and forward-looking information
contained in this Annual Information Form other
than as required by applicable laws (including
without limitation Section 5.8(2) of National
Instrument 51-102 (Continuous Disclosure
Obligations).
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of
this release.
|
